Moolec Science SA Receives Nasdaq Determination Letter
Ticker: MLECW · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1937737
Sentiment: neutral
Topics: listing-status, regulatory-filing
TL;DR
Nasdaq sent Moolec Science SA a determination letter on Nov 14, 2025.
AI Summary
On November 14, 2025, Moolec Science SA received a determination letter from Nasdaq. This Form 6-K filing is incorporated by reference into the company's existing registration statements on Form F-3 and Form S-8.
Why It Matters
This notification from Nasdaq is a crucial step in the company's compliance and listing process, potentially impacting its stock trading status.
Risk Assessment
Risk Level: medium — Receiving a determination letter from Nasdaq can indicate potential issues with listing requirements, which could lead to volatility.
Key Players & Entities
- Moolec Science SA (company) — Registrant
- Nasdaq (company) — Exchange
- November 14, 2025 (date) — Date of Nasdaq Determination Letter
- Form F-3 (document) — Incorporated by reference registration statement
- Form S-8 (document) — Incorporated by reference registration statement
FAQ
What is the specific nature of the Nasdaq Determination Letter received by Moolec Science SA?
The filing does not specify the content of the Nasdaq Determination Letter, only that it was received on November 14, 2025.
What are the registration numbers for the Form F-3 and Form S-8 mentioned?
The Form F-3 has registration number 333-283113 and the Form S-8 has registration number 333-282263.
When was this Form 6-K filed?
This Form 6-K was filed on November 20, 2025.
Where is Moolec Science SA's principal executive office located?
Moolec Science SA's principal executive offices are located at 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands.
Does Moolec Science SA file annual reports under Form 20-F or Form 40-F?
Moolec Science SA indicates it files annual reports under cover of Form 20-F.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 17.5 · Accepted 2025-11-20 16:15:04
Key Financial Figures
- $1.00 — inary shares had been below the minimum $1.00 per share requirement for the last 30 c
Filing Documents
- ea0266431-6k_moolec.htm (6-K) — 16KB
- 0001213900-25-113137.txt ( ) — 17KB
Forward-looking Statements
Forward-looking Statements This report contains “forward-looking “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company’s plan to regain compliance under the NASDAQ rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this report will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize